



PEPTECH
LIMITED

Peptech Limited
ABN 98 002 951 877

19-25 Khartoum Rd
Macquarie Park NSW 2113 Australia

Locked Bag 2053
North Ryde NSW 1670 Australia

Telephone +61 2 9870 8788
Facsimile +61 2 9870 8786

18 December 2006

ASX/MEDIA ANNOUNCEMENT

Peptech lists on AIM

Key Points

- **Peptech has successfully completed the AIM admission process**
- **Shares commenced first day of trade on Friday 15 December**
- **Listing increases international recognition and exposure to opportunities**

Australian biotechnology company Peptech Limited (ASX:PTD) today announced it had satisfied the Alternative Investment Market admission process resulting in the commencement of trade on AIM, a market regulated by the London Stock Exchange, under ticker symbol PTDx.

Peptech Chief Executive Officer Dr John Chiplin said that it is the Board's expectation that the listing will provide Peptech with the desired international exposure to build on this month's acquisition of the antibody assets of UK-based biotechnology company Scancell Limited and create an opportunity for the Company to take further advantage of strategic options in European markets.

"Peptech is committed to exploiting its ongoing revenue stream and robust cash position to pursue opportunities to strengthen its product pipeline and build scale through strategic acquisitions."

"Together with the proceeds from this month's sale of its 31.02% share in UK-based domain antibody company Domantis to GlaxoSmithKline (GSK), which generated GBP 71.3 million (approximately A\$178 million or \$1.08 per share), Peptech is extremely confident of its ability to leverage this position to execute its previously announced aggressive growth strategy and focus on expanding its product pipeline to create long term shareholder value."

Nomura Code Securities Limited is acting as Nominated Adviser and Broker to the Company.

Attached is the announcement of the first day of dealings released to the AIM market.

ENDS

Further information:

Dr John Chiplin
Chief Executive Officer
Peptech Limited
Tel: + 61 2 9870 8788

Released by:

Ms Stephanie Paul
Managing Director
Phillips Group
Mobile: 0418 753 062

About Peptech:

Peptech Limited focuses on the research and development of peptides and proteins in the areas of human pharmaceuticals and animal health. The company is positioned to become a globally recognised leader in biopharmaceutical development. For further information: www.peptech.com

Peptech Ltd

FIRST DAY OF DEALINGS ON AIM

- Leading the way in antibody and peptide development -

Peptech Ltd, (LSE:PTDx, ASX:PTD) (“Peptech” or the “Company”), the Australian biopharmaceutical company focused on the development of antibody and peptide products for the treatment of inflammatory diseases and cancer, today announces that depositary interests representing its Ordinary Shares have started dealing on AIM under the ticker symbol “PTDx”.

Peptech Highlights

- Profitable for the two years to 30 September 2006, and has revenue streams from its anti-TNF intellectual property and existing licensing deals related to two blockbuster drugs for rheumatoid arthritis, Humira® and Remicade®. These agreements are with Abbott and Centocor (Johnson & Johnson)
- Expected revenues payable to the Company under current licences range from A\$100 million to A\$130 million in total until August 2010
- Core expertise developed over 20 years is in the research and development of antibody and peptide products
- Human therapeutics pipeline includes products in development for the treatment of autoimmune and inflammatory diseases, (including rheumatoid arthritis, age-related macular degeneration, a major cause of blindness in people aged over 60) and cancer. The first of Peptech’s clinical candidates (its anti-TNF compound PN0621) is expected to enter Phase I clinical trials in the second quarter of 2007
- An animal health business focused on animal fertility products, including two marketed products, Ovuplant® and Suprelorin®

Strong cash reserves – A\$41 million at 30 September 2006, with an additional A\$178m (£71.3m) to be realised subject to the completion of the transaction in the 8 December announcement below.

Recent Announcements

- 8 December 2006: Peptech realised A\$178m (£71.3m) through the sale to GSK of its 31.02% shareholding in Domantis Limited, a UK-based leader in developing the next generation of antibody therapies
- 4 December 2006: Peptech acquired the antibody assets of UK based Scancell Limited at a cost of GBP 2 million, including two preclinical colorectal lead cancer-related antibodies to further strengthen its product pipeline

Nomura Code Securities Limited is acting as Nominated Adviser and Broker to the Company.

Commenting on today's announcement, Dr John Chiplin, Peptech's Chief Executive Officer, said: *"We are delighted to have joined AIM today. As a profitable biotech company, with royalty streams from two block buster drug agreements, together with our recent £71.3m realisation from the sale of our stake in Domantis, Peptech is now in an extremely strong position to leverage its experience within the antibody and peptide space. In essence, to build momentum in its human therapeutics pipeline in parallel to seeking out value-enhancing strategic acquisitions with a key focus of strengthening, enhancing and accelerating the development of our product pipeline."*

For further information, please contact:

Peptech Ltd

Dr John Chiplin, Chief Executive Officer
Niall Henderson, Chief Financial Officer

+61 (0)2 9870 8788

+61 (0)2 9870 8788

Buchanan Communications

Lisa Baderoon (lisab@buchanan.uk.com)
Mark Court
Rebecca Skye Dietrich / Catherine Breen

+44 (0)20 7466 5000

Nomura Code Securities

Charles Walker

+44 (0)20 7776 1206

About Peptech:

Peptech Limited focuses on the research and development of peptides and proteins in the areas of human pharmaceuticals and animal health. The company is positioned to become a globally recognised leader in biopharmaceutical development. For further information: www.peptech.com